Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.

Lupus Sci Med · 2022 · PMC8852715 · PMID 35169036

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the placebo-controlled dose-escalation phase, mean hybrid SELENA-SLEDAI scores showed a trend toward improvement in all groups, including placebo ( figure 1A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.